Bing

SEARCH HISTORY

Pa. (Photo: KEITH SRAKOCIC, AP file) PITTSBURGH — The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Stock in Mylan is surging 2.6% on the news in …
USA Today · 7/14/2014
Shares of Mylan Laboratories fell 5 percent yesterday, to $18.38, after regulatory scrutiny of a crucial product late last week and a day after the financier Carl C. Icahn offered to sell his stock in the company. Mr. Icahn, who has offered to acquire ...
New York Times · 7/19/2005
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has just approached Mylan N.V. (NASDAQ: MYL) with a public takeover bid valued at $82 per share in cash and stock. The offering would consist of approximately 50% in cash and 50% in stock. While …
24/7 Wall ST · 4/21/2015
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a proposal to acquire all of the outstanding shares of Mylan N.V. (NASDAQ: MYL) in a transaction valued at $82.00 per Mylan share, with …
Business Wire · 4/21/2015
NEW YORK (CNNMoney.com) -- Mylan Pharmaceuticals' stock plunged after the drugmaker said it was purchasing the generic arm of German drug giant Merck KGaA. Mylan (down $2.49 to $19.91, Charts) stock fell more than 13 percent Monday morning …
CNN Money · ByAaron Smith · 5/14/2007
Cecil-based generic drug giant Mylan Inc. announced Monday it would acquire a major chunk of Abbott Laboratories’ generic business outside the U.S. in an all-stock transaction through which Mylan would reincorporate in the Netherlands. The maneuver …
Pittsburgh Post-Gazette · ByLen Boselovic andPatricia Sabatini · 7/15/2014
Here’s where things stand: Teva wants to buy Mylan ... share which we estimate pegs the deal price at roughly $225 (post the initial stock move) and would have Mylan shareholders owning 61.8% of the combined company and Perrigo shareholders 38.2% ...
Barron's · 4/24/2015
Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
Los Angeles Times · 4/21/2015
When Teva Pharmaceuticals Industries made an unsolicitated offer to buy out Mylan for USD 40 billion in cash and stock, it ruffled shareholders of Natco Pharma a little. Natco had teamed up with Mylan to challenge the validity of Teva’s patented 20 mg ...
Money Control · 4/22/2015
While Mylan stock is being artificially supported by Teva stock, the price is still highly attractive, and the board will have a tough time justifying walking away, especially as the arbs buy stock from the long-only, strategic holders.
Market Realist · 4/29/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase